December 12, 2024 05:32 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Donald Trump vows to eliminate birthright citizenship after taking charge | No alliance with Congress in Delhi polls: AAP chief Arvind Kejriwal | Bengaluru techie's suicide: Atul Subhash's wife and her family booked | Bengaluru techie's suicide: Atul Subhash's wife and her family booked | INDIA bloc to knock on Supreme Court's doors over alleged EVM manipulation during Maharashtra polls | 'Babri Masjid should be rebuilt in Bengal's Murshidabad': TMC MLA Humayun Kabir sparks row | Rajnath Singh calls on Russian Prez Vladimir Putin in Moscow, discusses bilateral defence cooperation | Police to investigate conspiracy angle in Mumbai bus accident that killed 7 | Mamata Banerjee should lead INDIA bloc: Lalu Prasad Yadav | Opposition moves no-confidence motion against VP Jagdeep Dhankar in RS
Photo Courtesy: Unsplash

Dept of Pharma implementing PLI Scheme for Pharma at cost of Rs 15,000 cr

| @indiablooms | Aug 03, 2024, at 05:27 am

New Delhi: The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28, Ministry of Chemicals and Fertilizers informed Lok Sabha on Friday.

The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years, Union Minister of State for Chemicals and Fertilizers Anupriya Patel informed the Lok Sabha in response to a question.

The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc.

Orphan drugs are those drugs which are used for treatment of rare diseases.

Under the scheme, a total of eight orphan drugs have been approved for manufacturing.

The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows:

  1. Nitisinone used for treatment of Hereditary Tyrosinemia Type 1
  2. Nusinersen used for treatment of Spinal Muscular Atrophy
  3. Rufinamide used for treatment of Lennox-Gastaut syndrome.
  4. Sodium Phenyl Butyrate used for treatment of Urea Cycle Disorders
  5. Tiopronin used for Prevention of Cystine Nephrolithiasis
  6. Trientine Hydrochloride used for treatment of Wilson's disease
  7. Eliglustat used for treatment of Gaucher’s disease
  8. Cannabidiol used for treatment of Dravet-Lennox Gastaut syndrome

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.